"All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations

Journal of Virological Methods

Volumn 111, Issue 1, 2003, Pages 43-53

  Hachiya, Atsuko ^a   Matsuoka Aizawa, Saori ^a   Tsuchiya, Kiyoto ^a   Gatanaga, Hiroyuki ^a   Kimura, Satoshi ^a   Tatsumi, Masashi ^b   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Combination therapy; In vivo drug concentration; Inhibitory dilution; Phenotypic drug resistance assay

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ARTICLE; BIOASSAY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ISOLATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0038072875     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(03)00150-2     Document Type: Article

References (40)

1. Acosta E.P. Pharmacokinetic enhancement of protease inhibitors. J. Acquired Immune Defic. Syndr. 29:2002;S11-S18.
2. Balzarini J., Herdewijn P., De Clereq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264:1989;6127-6133.
3. Barry M.G., Khoo S.H., Veal G.J., Hoggard P.G., Gibbons S.E., Wilkins E.G., Williams O., Breckenridge A.M., Back D.J. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS. 10:1996;1361-1367.
4. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32:1997;194-209.
5. Baxter J.D., Mayers D.L., Wentworth J.D.N., Neaton D., Hoover M.L., Winters M.A., Mannheimer S.B., Thompson M.A., Abrams D.I., Brizz J.B.J., Ioannidis P.A., Merigan T.C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 14:2000;F83-F91.
6. Cammack N., Rouse P., Marr C.L., Reid P.J., Boehme R.E., Coates J.A., Penn C.R., Cameron J.M. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:1992;2059-2064.
7. Cohen C.J., Hunt S., Sension M., Farthing C., Conant M., Jacobson S., Nadler J., Verbiest W., Hertogs K., Ames M., Rinehart A.R., Graham N.M. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 16:2002;579-588.
8. Condra J.H., Petropoulos C.J., Ziermann R., Schleif W.A., Shivaprakash B.M., Emini E.A. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 182:2000;758-765.
9. Cozzi-Lepri A., Phillips A.N., Monforte A.A., Piersantelli N., Piersantelli N., Orani A., Petrosillo N., Leoncini F., Scerbo A., Tundo P., Abrescia N., Moroni M. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian cohort naïve antiretrovirals (I.Co.N.A.) study. J. Infect. Dis. 185:2002;1062-1069.
10. Descamps D., Flandre P., Calvez V., Peytavin G., Meiffredy V., Collin G., Delaugerre C., Robert-Delmas S., Bazin B., Aboulker J.P., Pialoux G., Raffi F., Brun-Vezinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. J. Am. Med. Assoc. 283:2000;205-211.
11. DHHS, 2001. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents.
12. Dionisio D., Vivarelli A., Zazzi M., Esperti F., Uberti M., Polidori M. Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch. Clin. Infect. Dis. 33:2001;706-709.
13. Dudley M.N., Graham K.K., Kaul S., Geletko S., Dunkle L., Browne M., Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:1992;480-485.
14. Dunne A.L., Mitchell F.M., Coberly S.K., Hellmann N.S., Hoy J., Mijch A., Petropoulos C.J., Mills J., Crowe S.M. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS. 15:2001;1471-1475.
15. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A.B., Schapiro J.M., Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 353:1999;2195-2199.
16. Durant J., Clevenbergh P., Garraffo R., Halfon P., Icard S., Giudice P.D., Montagne N., Schapiro J.M., Dellamonica P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy pharmacological data from the VIRADAPT study. AIDS. 14:2000;1333-1339.
17. Hachiya A., Aizawa-Matsuoka S., Tanaka M., Takahashi Y., Ida S., Gatanaga H., Hirabayashi Y., Kojima A., Tatsumi M., Oka S. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing Hela/CD4+ cell clone 1-10 (MAGIC-5). Antimicrob. Agents Chemother. 45:2001;495-501.
18. Harrigan P.R., Montaner J.S.G., Wegner S.A., Verbiest W., Miller V., Wood R., Larder B.A. Worldwide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS. 15:2001;1671-1677.
19. Havlir D.V., Hellman N.S., Petropoulos C.J., Whitcomb J.M., Collier A.C., Hirsch M.A., Tebas P., Sommadossi J.P., Richman D.D. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. J. Am. Med. Assoc. 283:2000;229-234.
20. Heeswijk R.P.G., Veldkamp A.I., Mulder J.W., Meenhorst P.L., Wit F.W.N.M., Lange J.M.A., Danner S.A., Foudraine N.A., Kakkelstein M.O., Reiss P., Beijnen J.H., Hoetelmans R.M.W. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 14:2000;F77-F82.
21. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkers D.K., Loveday C., Mellors J.M., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society - USA Panel. J. Am. Med. Assoc. 283:2000;2246-2417.
22. Ho H.T., Hitchcock M.J. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob. Agents Chemother. 33:1989;844-849.
23. Kemper C.A., Witt M.D., Keiser P.H., Dube M.P., Rorthal D.N., Leibowitz M., Smith D.S., Rigby A., Hellmann N.S., Lie Y.S., Leedom J., Richman D., McCutchan J.A., Haubrich R. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 15:2001;609-615.
24. Kewn S., Veal G.J., Haggard P.G., Barry M.G., Back D.J. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:1997;589-595.
25. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 15:2001;71-75.
26. Moore K.H.P., Barrett J.E., Shaw S., Pakes G.E., Churchus R., Kapoor A., Lloyd J., Barry M.G., Back D. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 13:1999;2239-2250.
27. Neu H. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. J. Am. Med. Assoc. 246:1981;1575-1578.
28. Patick A.K., Boritzki T.J., Bloom L.A. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:1997;2159-2164.
29. Peres-Elias M.J., Lanier R., Munoz V., Garcia-Arata I., Casado J.L., Marti-Belda P., Moreno A., Dronda F., Antela A., Marco S., Moreno S. Phenotypic testing predicts virological response in successive protease inhibitor-based regimens. AIDS. 14:2000;F95-F101.
30. Pieniazek D., Rayfield M., Hu D.J., Nkengasong J., Wiktor S.Z., Downing R., Biryahwaho B., Mastro T., Tanuri A., Soriano V., Lal R., Dondero T. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naïve individuals worldwide. AIDS. 14:2000;1489-1495.
31. Piras G., Nakade K., Yuasa S., Baba M. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1. AIDS. 11:1997;469-475.
32. Qian M., Chandrasena G., Ho R.J.Y., Unadkat J.D. Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 38:1994;2398-2403.
33. Ross L., Liao Q., Gao H., Pham S., Tolson J., Hertogs K., Larder B., Saag M.S. Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. AIDS Res. Hum. Retroviruses. 17:2001;1379-1385.
34. Snyder S., D'argenio D.Z., Weislow O., Bilello J.A., Drusano G.L. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob. Agents Chemother. 44:2000;1051-1058.
35. Sommadossi J.P. HIV protease inhibitors: pharmacologic and metabolic distinctions. AIDS. 13:1999;S29-S40.
36. Squires K.E., Gulick R., Tebas P., Santana J., Mulanovich V., Clark R., Yangco B., Marlowe S.I., Wright D., Cohen C., Cooley T., Mauney J., Uffelmann K., Schoellkopf N., Grosso R., Stevens M. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: selection of thymidine analog regimen therapy (START 1). AIDS. 14:2000;1591-1600.
37. St. Clair M.H., Pennington K.N., Rooney J., Barry D.W. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the inter-company collaboration protocol. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 10:1995;S83-91.
38. Stretcher B.N., Pesce A.J., Frame P.T., Stein D.S. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1994;1541-1547.
39. Toyoshima T., Kimura S., Muramatsu S., Takahagi H., Shimada K. A sensitive nonisotopic method for the determination of intracellular azidothymidine 5′-mono-, 5′-di-, and 5′-triphosphate. Anal. Biochem. 196:1991;302-307.
40. Young B., Johnson S., Bahktiari M., Shugarts D., Young R.K., Allen M., Ramey R.R. II, Kuritzkers D.R. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J. Infect. Dis. 178:1998;1497-1501.